144 related articles for article (PubMed ID: 31895802)
1. The prognostic relevance and expression of progranulin in adult patients with acute myeloid leukemia.
Qin J; Huang S; Qian J; Xu C; Li S; Yu S; Yan H; Wu M; Chen J; Ren H; Peng M
Medicine (Baltimore); 2020 Jan; 99(1):e18574. PubMed ID: 31895802
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia.
Huang YM; Wang YN; Zheng Y; Pan LL; Li Y; Li JG; Wang SY
Medicine (Baltimore); 2021 Feb; 100(8):e24614. PubMed ID: 33663070
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients.
El-Ghammaz AMS; Azzazi MO; Mostafa N; Hegab HM; Mahmoud AA
Clin Exp Med; 2020 May; 20(2):269-276. PubMed ID: 32006270
[TBL] [Abstract][Full Text] [Related]
4. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.
Göbel M; Eisele L; Möllmann M; Hüttmann A; Johansson P; Scholtysik R; Bergmann M; Busch R; Döhner H; Hallek M; Seiler T; Stilgenbauer S; Klein-Hitpass L; Dührsen U; Dürig J
PLoS One; 2013; 8(8):e72107. PubMed ID: 24009671
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients.
Azazzi MO; El-Ghammaz AMS; Mohamed HS
Hematol Transfus Cell Ther; 2023; 45(1):25-31. PubMed ID: 34294600
[TBL] [Abstract][Full Text] [Related]
6. Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.
Cao T; Ye Y; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Medicine (Baltimore); 2019 Jun; 98(23):e15948. PubMed ID: 31169718
[TBL] [Abstract][Full Text] [Related]
7. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
8. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of miR-96 in patients with acute myeloid leukemia.
Zhao J; Lu Q; Zhu J; Fu J; Chen YX
Diagn Pathol; 2014 Mar; 9():76. PubMed ID: 24678958
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
12. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
13. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Pashaiefar H; Yaghmaie M; Tavakkoly-Bazzaz J; Ghaffari SH; Alimoghaddam K; Momeny M; Izadi P; Izadifard M; Kasaeian A; Ghavamzadeh A
Genet Test Mol Biomarkers; 2018 Jun; 22(6):343-349. PubMed ID: 29812960
[TBL] [Abstract][Full Text] [Related]
14. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
16. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
[TBL] [Abstract][Full Text] [Related]
17. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia.
Li X; Zhu H; Zhang Y; Zhao W; Mi J; Hu J; Li J
Acta Haematol; 2016; 135(4):217-23. PubMed ID: 26967450
[TBL] [Abstract][Full Text] [Related]
18. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
20. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
